

Peer Review File

Article Information: <https://dx.doi.org/10.21037/apm-23-545>

Reviewer Comments

The commentary is well written and permit to appreciate pros and cons in the manuscript of Benoit et al. However, is some point it resulted redundant.

Point by point:

- line 147-148: this sentence is not clear. Please revise it.

Reply: Thank you for this comment, we have added in “ZUMA-1” to cohort 4 which is the earlier intervention with steroids and tocilizumab as outlined in the registrational trial.

- line 162-167: this consideration was already explained in the text and appear out of context in this point.

Reply: This is a valid point. To avoid redundancy, we have completely removed that sentence.